Cepheid
Cepheid is a global leader in molecular diagnostics, dedicated to improving healthcare by developing, manufacturing, and marketing automated, easy-to-use molecular systems and tests. Their mission is to provide rapid, accurate, and actionable genetic testing for a wide range of infectious diseases, oncology, and human genetics. Cepheid's flagship GeneXpert System delivers scalable, sample-to-answer PCR testing for institutions of any size, supporting both centralized and decentralized care. The company is committed to expanding access to high-quality diagnostics worldwide, supporting public health initiatives, driving innovation in molecular testing, and advancing sustainability and responsible business practices.
Patents
Thermal control device and methods utilizing temperature distribution modeling
2025-06-03 • US-12321183-B2
View DetailsWhat We Do
A modular, scalable real-time PCR diagnostic platform that automates sample preparation, amplification, and detection for a broad menu of tests.
A compact, CLIA-waived version of the GeneXpert system designed for point-of-care molecular testing.
High-throughput, automated PCR systems for molecular diagnostic testing, supporting up to 2,000 tests per day.
Software solution enabling multiplexing using 10-color technology for GeneXpert platforms.
Intelligent process management software for GeneXpert Infinity systems, offering walkaway simplicity, real-time data management, and LIS capability.
Connectivity solution that transforms insights into action, supporting integration with laboratory information systems.
Application Area
Vaccines
Diagnostics
Key People
President
Vice President, Value and Access
Senior Vice President, Research & Development
Senior Vice President, Regulatory and Clinical Affairs
Senior Vice President, Global Commercial Operations
Vice President, Global Danaher Business System Leader
News & Updates
Cepheid's Xpert MTB/RIF test received World Health Organization endorsement as a major milestone for TB and MDR-TB care delivery.
Cepheid rapidly developed and received FDA Emergency Use Authorization for its Xpert Xpress SARS-CoV-2 test during the COVID-19 pandemic.
Cepheid launched the first molecular test to detect HCV RNA levels directly from a fingerstick of blood.
Article discussing the trade-offs between rapid antigen tests and PCR, highlighting the risk of missed diagnoses with antigen testing.
Review of the strengths of PCR-based molecular testing compared to antigen testing and the benefits of point-of-care molecular diagnostics.
Article on the importance of accurate diagnostics for vaginitis, including bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis.
Overview of a public health initiative to eradicate hepatitis C in small communities.
Article on Cepheid's innovation and expansion through strategic partnerships.
Cepheid is participating in the CoLab event in Wellington, New Zealand, October 22-23, 2025.
Cepheid is participating in the Global Health Exhibition in Riyadh, Saudi Arabia, October 27-30, 2025.
Cepheid is participating in NAPCON in Patna, India, November 30-December 2, 2025.
Cepheid is participating in MICROCON in Delhi, India, November 30-December 2, 2025.
Cepheid is participating in ACIPC in Hobart, Australia, November 16-19, 2025.
Cepheid is participating in TSLM in Taipei, Taiwan, December 4-7, 2025.
Cepheid is participating in AGOICON in Kolkata, India, December 8, 2025.
Cepheid is participating in NATCON in Kolkata, India, December 23-25, 2025.